Normal dynamic MRI enhancement patterns of the upper abdominal organs: Gadoxetic acid compared with gadobutrol

American Journal of Roentgenology

Volumn 193, Issue 5, 2009, Pages 1318-1323

  Kühn, Jens Peter ^a   Hegenscheid, Katrin ^a   Siegmund, Werner ^a   Froehlich, Claus Peter ^a   Hosten, Norbert ^a   Puls, Ralf ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Dynamic MRI; Gadobutrol; Gadolinium based contrast agent; Gadoxetic acid; Upper abdominal organs

Indexed keywords

CONTRAST MEDIUM; ECHOVIST; GADOBUTROL; GADOLINIUM; GADOXETIC ACID;

ABDOMINAL AORTA; ADULT; AGED; ARTICLE; BREATH HOLDING; CONCENTRATION (PARAMETERS); CONTRAST ENHANCEMENT; CONTROL GROUP; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIGESTIVE SYSTEM; DRUG CLEARANCE; DRUG EXCRETION; FEMALE; HEPATIC ARTERY; HEPATOBILIARY RADIOGRAPHY; HUMAN; KIDNEY CLEARANCE; KIDNEY CORTEX; KIDNEY MEDULLA; LIVER; LIVER BLOOD VESSEL; LIVER VEIN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS; PRIORITY JOURNAL; PROTEIN BINDING; SIGNAL NOISE RATIO; SPLEEN; VOLUMETRY;

ABDOMEN; ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; STATISTICS, NONPARAMETRIC;

EID: 70449511361     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.09.2412     Document Type: Article

References (26)

1. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging-a multicenter phase III clinical study. Radiology 2000; 215:727-736 (Pubitemid 30346007)
2. Oudkerk M, Torres CG, Song B, et al. Characterization of liver lesions with mangafodipir trisodium- enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT. Radiology2002; 223:517-524
3. Bluemke DA, Sahani D, Amendola M, et al. Effi- cacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 2005; 237:89-98 (Pubitemid 41346150)
4. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid- enhanced MR images with intraoperative findings. Radiology 2004; 230:266-275 (Pubitemid 37549812)
5. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234:468-478 (Pubitemid 40139918)
6. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver- properties, clinical development, and applications. Eur Radiol 2003; 13:1266-1276 (Pubitemid 36790627)
7. Reimer P, Tombach B. Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Eur Radiol 1998; 8:1198-1204 (Pubitemid 128662777)
8. Imam K, Bluemke DA. MR imaging in the evaluation of hepatic metastases. Magn Reson Imaging Clin N Am 2000; 8:741-756
9. Vogl TJ, Kümmel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOBDTPA and Gd-DTPA. Radiology 1996; 200:59-67 (Pubitemid 26197732)
10. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)- enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008; 18:457-467 (Pubitemid 351248177)
11. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996; 199:177-183 (Pubitemid 26098637)
12. Clément O, Mühler A, Vexler VS, et al. Comparison of Gd-EOB-DTPA and Gd-DTPA for contrast- enhanced MR imaging of liver tumors. J Magn Reson Imaging 1993; 3:71-77
13. Mühler A, Clément O, Vexler V, et al. Hepatobiliary enhancement with Gd-EOB-DTPA: comparison of spin-echo and STIR imaging for detection of experimental liver metastases. Radiology 1992; 184:207-213
14. Stern W, Schick F, Kopp AF, et al. Dynamic MR imaging of liver metastases with Gd-EOB-DTPA. Acta Radiol 2000; 41:255-262
15. Bellin MF, Vasile M, Morel-Precetti S, et al. Currently used non-specific extracellular MR contrast media. Eur Radiol 2003; 13:2688-2698 (Pubitemid 37527075)
16. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40:715-724 (Pubitemid 41546838)
17. Weinmann HJ, Schuhmann-Giampieri G, Schmitt- Willich H, et al. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1991; 22:233-237
18. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, et al. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992; 183:59-64
19. Zizka J, Klzo L, Ferda J, et al. Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol. Eur J Radiol 2007; 62:186-191 (Pubitemid 46560352)
20. Yoshikawa K, Inoue Y, Shimada M, et al. Contrast- enhanced MR angiography in rats with hepatobiliary contrast agents. Magn Reson Imaging 2004; 22:937-942 (Pubitemid 38993523)
21. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997; 32:780-796 (Pubitemid 28053510)
22. Knopp MV, Schoenberg SO, Rehm C, et al. Assessment of gadobenate dimeglumine for magnetic resonance angiography: phase I studies. Invest Radiol 2002; 37:706-715 (Pubitemid 35429192)
23. Thurnher S, Miller S, Schneider G, et al. Diagnostic performance of gadobenate dimeglumine enhanced MR angiography of the iliofemoral and calf arteries: a large-scale multicenter trial. AJR 2007; 189:1223-1237 (Pubitemid 350033021)
24. Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology 2001; 218:27-38
25. Hamm B, Staks T, Mühler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195:785-792
26. Zangos S, Hammerstingl R, Mack MG, et al. Renal enhancement and excretion of the hepatobiliary contrast agent Gd-EOB-DTPA [in German]. Rofo 2001; 173:1034-1040 (Pubitemid 33101238)